Sepetaprost  (Synonyms: ONO-9054)

Sepetaprost (ONO-9054) is a dual agonist of the prostaglandin E3 receptor and prostaglandin F receptor. Sepetaprost reduces intraocular pressure in animal models. Sepetaprost is applicable for research on ocular hypertension and open-angle glaucoma^[1][2].

Sepetaprost (0.002%; topical ocular instillation; single dose) exerts a potent and long-lasting intraocular pressure (IOP)-lowering effect on normotensive male cynomolgus monkeys by activating the EP3 receptor, with significant IOP reduction observed and increased aqueous humor outflow facility in cynomolgus monkeys^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

482.56

C₂₆H₃₆F₂O₆

1262873-06-2

O=C(OC(C)C)CCC[C@H]1CC[C@@]([C@@H](/C=C/[C@@H](O)COC2=CC(F)=CC=C2F)[C@H](O)C3)([H])[C@@]3([H])OC1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Suto F, et al. A Novel Dual Agonist of EP3 and FP Receptors for OAG and OHT: Safety, Pharmacokinetics, and Pharmacodynamics of ONO-9054 in Healthy Volunteers. Invest Ophthalmol Vis Sci. 2015;56(13):7963-7970.  [Content Brief]

  [2]. Maki K, et al. The Role of EP3 Agonism in Intraocular Pressure-Lowering by Sepetaprost, a Novel Dual Agonist of FP and EP3 Receptors, in Monkeys. J Ocul Pharmacol Ther. 2026;42(3):172-178.  [Content Brief]